25,729 articles
NAVIGATOR trial (NCT03347279)
NAVIGATOR (NCT03347279) was the pivotal phase 3 tezepelumab trial: 1061 patients aged 12-80 with severe uncontrolled asthma, 210 mg subcutaneous every 4 weeks for 52 weeks, reducing exacerbation rate 56% versus placebo.
Navitoclax
Navitoclax (ABT-263, A-855071.0) is an oral Bcl-2 family inhibitor targeting Bcl-2, Bcl-XL, and Bcl-w, studied in lymphoma, CLL, and solid tumors; development limited by Bcl-XL-driven thrombocytopenia, leading to venetoclax.
Navtemadlin
Navtemadlin, formerly AMG-232 and KRT-232, is an investigational oral MDM2 inhibitor that restores p53 activity in cancer cells, developed by Amgen and now held by Kartos Therapeutics.
Naxitamab
Naxitamab (Danyelza, naxitamab-gqgk, hu3F8) is a humanized anti-GD2 monoclonal antibody FDA-approved in 2020 with GM-CSF for relapsed/refractory high-risk neuroblastoma in bone or bone marrow; Trial 201 showed 50% ORR.
Naxos disease
Naxos disease, also called keratoderma with woolly hair type I, is a rare autosomal recessive cardiocutaneous disorder combining arrhythmic right ventricular cardiomyopathy, woolly hair, and palmoplantar keratoderma, usually caused by a homozygous JUP plakoglobin deletion.
NAYANAMRTANJANA
Nayanamrtanjana (Nayanāmṛtāñjana) is a classical Ayurvedic anjana collyrium for eye diseases, listed in the Ayurvedic Formulary of India from Sharangadhara Samhita, Uttara Khanda 13, containing kajjali and herbs.
Nayopayam kvatha curna
Nayopayam kvatha curna (Nāyopāyam kvātha cūrṇa), an Ayurvedic polyherbal decoction of Sida cordifolia, Cuminum cyminum, and Zingiber officinale in classical ratios 3:2:1 or 10:1:1, used for respiratory ailments, heart problems, and postnatal care; AFI dose 48 g.
NBL-015 (anti-Claudin 18.2 antibody)
NBL-015 (FL-301) is a fully human anti-Claudin 18.2 monoclonal antibody from NovaRock Biotherapeutics (CSPC), in phase 1 trials (NCT05153096) for CLDN18.2-positive solid tumors, licensed ex-Greater China to Flame Biosciences in 2021.
NBTXR3
NBTXR3, also known as JNJ-1900 or Hensify, is a radioenhancer of hafnium oxide nanoparticles injected into tumors to amplify radiotherapy, developed by Nanobiotix and licensed to Janssen.
NC-37
NC-37 (RRID:CVCL_3042; ATCC CCL-214, JCRB IFO50039) is an EBV-positive human B-lymphoblast cell line long distributed as healthy-donor derived but shown by DNA fingerprinting to be a Raji (Burkitt's lymphoma) derivative; ICLAC-00330.
NC/Nga
NC/Nga (Nishiki-nezumi Cinnamon/Nagoya) is an inbred laboratory mouse strain from Japanese fancy mice that spontaneously develops atopic dermatitis-like skin lesions with high IgE under conventional, but not SPF, housing; the first AD mouse model.
NCE-G 120
NCE-G 120 (G120, NeuroChirurgie Eppendorf-Glioma 120), CVCL_N742, is a human glioblastoma cancer cell line from a 59-year-old male, left temporo-parietal junction, used in p53, radiation, and transcriptomic studies.
NCE-G 44
NCE-G 44 (G44, GL44; CVCL_N727) is a human glioblastoma cell line from a 64-year-old woman's left parietal lobe, established at University Hospital Hamburg-Eppendorf, with a TP53 p.Glu224Ter mutation and high MGMT-driven temozolomide resistance.
NCI-H128
NCI-H128 (H128, CVCL_1460, ATCC HTB-120) is a human small cell lung carcinoma cell line established in 1980 from a pleural effusion of a 60-year-old man; suspension-growing, aneuploid with 3p deletion, tumorigenic in nude mice.
NCI-H1339
NCI-H1339 (H1339, CVCL_A472) is a human small cell lung cancer cell line from a 49-year-old female's pleural effusion, TP53 IVS9+1G>T mutant, partially contaminated with NCI-H157 or NCI-1264, and discontinued at ATCC and DSMZ.
NCI-H187
NCI-H187 (H187, CVCL_1501, ATCC CRL-5804) is a human small cell lung cancer cell line from a 47-year-old male's pleural effusion; classic neuroendocrine SCLC model with TP53 S241C, RB loss, and c-kit/N-myc expression.
NCI-H226
NCI-H226 (H226, HUT-226), human mesothelioma cancer cell line from a male pleural effusion, established 1980, ATCC CRL-5826, NCI-60 panel member, CDKN2A-deleted and NF2-null.
NCI-H289
NCI-H289 (H289, CVCL_A554) is a human small cell lung cancer cell line established in 1985 from a pleural effusion of a 45-year-old woman; a variant-subclass SCLC line paired with NCI-BL289 from the same patient.
NCI-H378
NCI-H378 (H378, CVCL_1560, ATCC CRL-5808) is a human small cell lung cancer cell line from a metastatic pleural effusion, expressing classic SCLC markers, c-kit, amplified L-myc, and homozygous TP53 p.Tyr163Cys.
NCI-H647
NCI-H647 (H647, CVCL_1574, ATCC CRL-5834) is a human lung cancer cell line from a 56-year-old male with stage 3A adenosquamous carcinoma, established 1983 from pleural effusion; KRAS Gly13Asp, TP53 splice mutant, used in NSCLC and drug-screening research.
NCI-H720
NCI-H720 (H720, CVCL_1583, ATCC CRL-5838) is a human lung carcinoid cell line from a male with atypical carcinoid, established 1984 by Gazdar and Minna; suspension-growing, TP53 and RB1 mutant, standard AC model paired with NCI-H727.
NCI-H727
NCI-H727 is a human cancer cell line derived from a bronchial carcinoid lung tumor, established in 1984 and widely used as a research model of pulmonary neuroendocrine tumors.
NCI-H847
NCI-H847 (NCIH847, H847; CVCL_1596) is a human small cell lung cancer cell line established in 1984 from a 63-year-old man's metastatic pleural effusion, ATCC CRL-5846, TP53 R158L, used in NCI SCLC pharmacogenomic panels.
NCI-H929
NCI-H929 (H929, CVCL_1600) is a human IgA kappa multiple myeloma cell line established in 1986 from a pleural effusion, with rearranged c-myc, NRAS Gly13Asp, EBV-negative, held at ATCC CRL-3580 and DSMZ ACC-163.
NCOM study
NCOM study (NCT06219083), a prospective multicenter cohort in Xi'an, China, tracking nutritional status (mPG-SGA) and clinical outcomes in 1,538 cancer patients across 11 hospitals over 5 years.
NCRT-LABC trial
NCRT-LABC (NCT06697938) is a randomized trial at Sichuan Cancer Hospital, Chengdu, comparing preoperative SBRT plus chemotherapy versus neoadjuvant chemotherapy alone in 148 patients with luminal-type locally advanced breast cancer, primary endpoint pCR.
NDCVC-01 trial
NDCVC-01 (NCT06652191), Non Dilation on the Central Venous Catheterization, a randomized non-inferiority trial at Sun Yat-sen University's Sixth Affiliated Hospital testing omission of the skin-dilation step in internal jugular CVC insertion in 336 patients.
NDE1-related microhydranencephaly
NDE1-related microhydranencephaly (MHAC, OMIM 605013) is an autosomal recessive disorder from biallelic NDE1 variants, causing extreme microcephaly, absent cerebral hemispheres, ventricular dilation, and severe disability.
Neal A. Vanselow
Neal Arthur Vanselow (1932–2016) was an American allergist-immunologist and academic health-center leader who served as dean, chancellor, and vice president at Arizona, Nebraska, Minnesota, and Tulane, and joined the Institute of Medicine in 1989.
Neal D. Barnard
Neal D. Barnard is an American physician and clinical researcher who heads the Physicians Committee for Responsible Medicine and studies plant-based diets for type 2 diabetes.